TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Up 31.4% – Should You Buy?

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW)’s stock price shot up 31.4% on Wednesday. The company traded as high as $0.9399 and last traded at $0.7360. 1,810 shares traded hands during mid-day trading, a decline of 63% from the average daily volume of 4,865 shares. The stock had previously closed at $0.56.

TriSalus Life Sciences Stock Performance

The firm has a 50 day moving average price of $0.86 and a two-hundred day moving average price of $0.97.

Institutional Trading of TriSalus Life Sciences

An institutional investor recently bought a new stake in TriSalus Life Sciences stock. State Street Corp acquired a new stake in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 610,963 shares of the company’s stock, valued at approximately $2,780,000.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is an oncology-focused medical technology and therapeutics company developing products intended to improve the treatment of solid tumors, particularly cancers of the liver and pancreas. The company’s approach is designed to address the biological and physical barriers that can limit the delivery of therapies into tumors.

Its primary technology is Pressure-Enabled Drug Delivery (PEDD), which uses specialized infusion systems to administer treatments directly to tumors or tumor-feeding blood vessels.